Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
Trial ID or NCT#
NCT00679354
Status
NOT RECRUITING
Purpose
This phase II trial studies how well cilengitide works in treating younger patients with recurrent or progressive high-grade glioma that has not responded to standard therapy. Cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor.
Official Title
Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma
Eligibility Criteria
Ages Eligible for Study: Younger than 21 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Exclusion Criteria:
Investigator(s)
Neyssa Marina
Contact us to find out if this trial is right for you.
Contact
Peds Hem/Onc CRAs
650-723-5535
View on ClinicalTrials.gov
